Bullish SLS thesis: FDA Bayesian methodology and REGAL Phase 3 superiority trigger could stop the trial early and spark a bidding war among AbbVie, Merck, Pfizer, and Lilly for SLS's WT1 vaccine platform.
SLS — LONG The author argues the FDA's January 12, 2026 Bayesian methodology guidance lets the IDMC stop the REGAL Phase 3 trial early based on probability of success rather than a rigid event count. With 72 of 80 required events banked as of late 2025, a survival superiority signal could trigger a trial stop as early as February 1, 2026. The stated catalyst is the February 2026 superiority trigger, and the trade is positioned for an early data readout.
The FDA’s January 12, 2026 guidance on Bayesian Methodology is the primary driver for this trade. It allows the IDMC to stop trials early based on the probability of success rather than just a rigid death count.
SLS — LONG The author claims December 2025 Phase 2 data showed SLS009 plus Venclexta and azacitidine achieved a 46% to 58% response rate and median survival of 8.9 months versus 2.5 months for patients failing Venclexta, by suppressing MCL-1 to overcome resistance. AbbVie terminated its own Phase 3 VIALE-T study in October 2025, which the author says leaves SLS as the AML maintenance leader and makes AbbVie the most logical buyer to protect its multi-billion-dollar Venclexta franchise. The concrete catalysts cited are the December 2025 data and AbbVie's trial termination.
Data from December 2025 showed SLS009 overcame resistance to AbbVie's Venclexta, tripling life expectancy in failing patients. This "key" makes SLS an essential partner to protect multi-billion dollar franchises.
SLS — LONG The author argues Merck needs $1B–$15B bolt-on acquisitions to bridge a $30B+ Keytruda revenue cliff in 2028, and SLS fits because GPS is in Phase 3 and already in a GPS plus Keytruda ovarian cancer collaboration. The author contends Merck knows the data and must buy SLS to protect Keytruda, or AbbVie or Pfizer will. The stated horizon is the 2028 Keytruda cliff, with no specific acquisition date.
The Logic:** Merck knows the data better than anyone. If they see GPS working as a "vaccine" that makes Keytruda work better, they have to buy it. If they don't, AbbVie or Pfizer will.
SLS — LONG The author claims Pfizer CEO Albert Bourla and SLS CEO Angelos Stergiou share a high-profile Greek diaspora connection, and a Stergiou LinkedIn post about missing an event with his "friend" Bourla was a "tell." Pfizer needs to replace lost COVID revenue and has been buying oncology assets, so buying SLS would be both strategic and a "hometown hero" move for Bourla. The author presents this as a sleeper acquisition path rather than a dated catalyst.
There is a high-profile personal connection between Pfizer CEO Albert Bourla and SLS CEO Angelos Stergiou. Pfizer needs to replace lost COVID revenue and has been aggressively buying oncology assets like Seagen.
SLS — LONG The author argues Eli Lilly is using an NVIDIA SuperPOD AI system and T-cell partnerships to find "immune priming" assets, which points to SLS's WT1 vaccine that generates T-cell responses in 80% of patients. The author says Lilly wants to own the delivery mechanism for immune priming as it seeks to overtake Merck in oncology revenue by late 2026. The stated catalyst is Lilly's AI-driven search and existing BioNTech/Keytruda combination activity, with no specific bid date.
Lilly is using a NVIDIA SuperPOD to find "Immune Priming" assets. Their AI points directly to GPS’s ability to generate T-cell responses in 80% of patients, making them a sleeper candidate to hijack a deal.
SLS — LONG The author claims SLS's GPS targets WT1, ranked the #1 cancer antigen by the National Cancer Institute, making it a platform play across more than 20 cancer types from AML to ovarian and glioblastoma. Because WT1 is overexpressed in major cancers, the author views GPS as a plug-and-play asset and SLS as a Phase 3 registrational company with zero competition in AML maintenance. The thesis is a long-term platform value argument without a specific catalyst date.
GPS targets WT1, ranked the #1 cancer antigen by the National Cancer Institute. This makes SLS a platform play for 20+ cancer types, from AML to Ovarian and Glioblastoma.
SLS — LONG The author states short interest is about 30% with 68%+ institutional ownership, and a superiority stop would create a "Double Whammy" where shorts must cover into limited available shares. The catalyst is the potential February 1 superiority stop, which the author expects to squeeze shorts. The thesis is explicitly a trading setup based on high short interest and tight float.
Short interest is currently high at \~30%, with 68%+ institutional ownership. A "Superiority Stop" creates a "Double Whammy" where shorts must cover into a market with limited available shares.
SLS — LONG The author argues that a bidding war for the #1 ranked immunotherapy target could value SLS at $10B–$15B, implying a share price of $100–$115. The mechanism is strategic competition among AbbVie, Merck, Pfizer, and Eli Lilly for SLS's Phase 3 WT1 platform. No specific deadline is given for a deal, though the REGAL superiority trigger is positioned as the near-term catalyst.
If a bidding war breaks out for the #1 ranked target in immunotherapy, a $10B–$15B buyout puts the share price in the $100–$115 range.
This Reddit post, published January 27, 2026, features u/LionLukeWay discussing SLS. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/LionLukeWay · Tickers: SLS